166 related articles for article (PubMed ID: 36748213)
1. VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells.
Chen T; Yang F; Dai X; Yu Y; Sun Y; Wu X; Li R; Zhou Q
Curr Cancer Drug Targets; 2023; 23(6):482-495. PubMed ID: 36748213
[TBL] [Abstract][Full Text] [Related]
2. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modifications control loss of adhesion and aggressiveness of cancer stem cells derived from head and neck squamous cell carcinoma with intrinsic resistance to cisplatin.
Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida LO
Arch Oral Biol; 2022 Sep; 141():105468. PubMed ID: 35679799
[TBL] [Abstract][Full Text] [Related]
4. 3-MA Enhanced Chemosensitivity in Cisplatin Resistant Hypopharyngeal Squamous Carcinoma Cells via Inhibiting Beclin -1 Mediated Autophagy.
Zhang J; Mao W; Liu Y; Ding J; Wang J; Yu Z; Huang R; Yang S; Sun Y; Dong P
Curr Pharm Des; 2021; 27(7):996-1005. PubMed ID: 33349212
[TBL] [Abstract][Full Text] [Related]
5. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
6. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
7. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
8. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
10. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
11. Kaempferol Induces Cell Death and Sensitizes Human Head and Neck Squamous Cell Carcinoma Cell Lines to Cisplatin.
Catalán M; Rodríguez C; Olmedo I; Carrasco-Rojas J; Rojas D; Molina-Berríos A; Díaz-Dosque M; Jara JA
Adv Exp Med Biol; 2021; 1326():95-109. PubMed ID: 33368015
[TBL] [Abstract][Full Text] [Related]
12. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.
Sobral LM; Sousa LO; Coletta RD; Cabral H; Greene LJ; Tajara EH; Gutkind JS; Curti C; Leopoldino AM
Mol Cancer; 2014 Feb; 13():32. PubMed ID: 24555657
[TBL] [Abstract][Full Text] [Related]
13. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with acetazolamide and cisplatin enhances the chemosensitivity of human head and neck squamous cell carcinoma TU868 cells.
Jia T; Ming SX; Cao QQ; Xu FL
Arch Oral Biol; 2020 Nov; 119():104905. PubMed ID: 32947166
[TBL] [Abstract][Full Text] [Related]
15. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
[TBL] [Abstract][Full Text] [Related]
16. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
18. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
19. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
[TBL] [Abstract][Full Text] [Related]
20. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
